| Clinical and virological data of the first cases of COVID-19 in Europe: a case series FX Lescure, L Bouadma, D Nguyen, M Parisey, PH Wicky, S Behillil, ... The Lancet Infectious Diseases 20 (6), 697-706, 2020 | 1392 | 2020 |
| Type 1 interferons as a potential treatment against COVID-19 E Sallard, FX Lescure, Y Yazdanpanah, F Mentre, N Peiffer-Smadja Antiviral research 178, 104791, 2020 | 627 | 2020 |
| Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ... PLoS medicine 13 (3), e1001967, 2016 | 603 | 2016 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 543 | 2021 |
| Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R E Comets, K Brendel, F Mentré Computer methods and programs in biomedicine 90 (2), 154-166, 2008 | 515 | 2008 |
| Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin E Maubec, P Petrow, I Scheer-Senyarich, P Duvillard, L Lacroix, J Gelly, ... Journal of Clinical Oncology 29 (25), 3419-3426, 2011 | 485 | 2011 |
| Optimal design in random-effects regression models F Mentre, A Mallet, D Baccar Biometrika 84 (2), 429-442, 1997 | 416 | 1997 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 394 | 2022 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 387 | 2021 |
| Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide K Brendel, E Comets, C Laffont, C Laveille, F Mentré Pharmaceutical research 23, 2036-2049, 2006 | 384 | 2006 |
| Model evaluation of continuous data pharmacometric models: metrics and graphics THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ... CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017 | 360 | 2017 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 303 | 2022 |
| Hand contamination before and after different hand hygiene techniques: a randomized clinical trial JC Lucet, MP Rigaud, F Mentre, N Kassis, C Deblangy, A Andremont, ... Journal of hospital Infection 50 (4), 276-280, 2002 | 255 | 2002 |
| Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load A Gonçalves, J Bertrand, R Ke, E Comets, X De Lamballerie, D Malvy, ... CPT: pharmacometrics & systems pharmacology 9 (9), 509-514, 2020 | 238 | 2020 |
| Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ... Proceedings of the National Academy of Sciences 118 (8), e2017962118, 2021 | 225 | 2021 |
| Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004 K Brendel, C Dartois, E Comets, A Lemenuel-Diot, C Laveille, ... Clinical pharmacokinetics 46, 221-234, 2007 | 224 | 2007 |
| Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques P Amarenco, S Davis, EF Jones, AA Cohen, WD Heiss, M Kaste, ... Stroke 45 (5), 1248-1257, 2014 | 222 | 2014 |
| Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials V Madelain, THT Nguyen, A Olivo, X De Lamballerie, J Guedj, AM Taburet, ... Clinical pharmacokinetics 55 (8), 907-923, 2016 | 216 | 2016 |
| Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model A Samson, M Lavielle, F Mentré Computational Statistics & Data Analysis 51 (3), 1562-1574, 2006 | 215 | 2006 |
| Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action C Bazzoli, V Jullien, CL Tiec, E Rey, F Mentré, AM Taburet Clinical pharmacokinetics 49, 17-45, 2010 | 204 | 2010 |
Emmanuelle CometsINSERM (National Institute of Health and Medical Research, France)Verified email at inserm.fr